GE, Takeda team up to tackle liver disease

By staff writers

November 11, 2014 -- GE Healthcare and Takeda Pharmaceutical have inked an agreement to develop new therapeutic drugs for liver disease.

The partnership will focus on hepatic fibrosis, a key factor in the diagnosis and treatment of liver disease; currently, hepatic fibrosis is most commonly diagnosed using liver biopsy. GE will contribute its MR elastography technology to generate a liver stiffness map for research and development work Takeda is conducting on liver disease. The firms hope to develop therapeutic drugs and new diagnostic technologies for liver diseases via their collaboration.

Terms of the deal are not being disclosed.

Copyright © 2014

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking